PapersFlow Research Brief
Cancer therapeutics and mechanisms
Research Guide
What is Cancer therapeutics and mechanisms?
Cancer therapeutics and mechanisms is the study of molecular mechanisms underlying anticancer drug actions, resistance development, and targeted inhibition strategies, including roles of ATP-dependent transporters, EGFR mutations, ALK rearrangements, and DNA-damaging agents like cisplatin and irinotecan.
This field encompasses over 53,210 works examining drug resistance, inhibitor mechanisms, and genetic predictors in cancer treatment. Key focuses include ATP-dependent transporters contributing to multidrug resistance and EGFR/ALK-targeted therapies in lung cancer. Research highlights cisplatin's cytotoxic action via DNA damage and irinotecan's efficacy in colorectal cancer when combined with fluorouracil.
Topic Hierarchy
Research Sub-Topics
DNA Topoisomerase I Inhibitors
This sub-topic examines the molecular mechanisms, clinical efficacy, and resistance profiles of topoisomerase I inhibitors like irinotecan and topotecan in cancer chemotherapy. Researchers investigate structure-activity relationships, pharmacokinetics, and strategies to overcome tumor resistance.
DNA Topoisomerase II Poisons
Focuses on etoposide, doxorubicin, and anthracyclines that stabilize topoisomerase II-DNA cleavage complexes, leading to DNA damage in proliferating cancer cells. Studies explore enzyme isoform specificity (alpha vs beta), cardiotoxicity mechanisms, and combination regimens.
Topoisomerase Genetic Variants
Investigates polymorphisms in TOP1 and TOP2A genes that influence enzyme activity, drug sensitivity, and patient outcomes in chemotherapy. Researchers develop pharmacogenomic models for personalized dosing and toxicity prediction.
Topoisomerase Inhibition Resistance
Explores mechanisms of acquired and intrinsic resistance including drug efflux pumps, topoisomerase mutations, and DNA repair pathway activation. Research identifies biomarkers and novel combination strategies to restore sensitivity.
Topoisomerases Genomic Stability
Studies the role of topoisomerases in preventing DNA tangling, replication stress, and chromosomal aberrations during cell division. Investigates how topoisomerase dysfunction contributes to carcinogenesis and therapy-induced secondary malignancies.
Why It Matters
Cancer therapeutics and mechanisms directly inform clinical strategies to overcome resistance and improve outcomes in chemotherapy and targeted therapies. For instance, Michael M. Gottesman et al. (2002) in "Multidrug resistance in cancer: role of ATP–dependent transporters" detailed how efflux pumps reduce drug accumulation, affecting treatments across multiple cancers with 5431 citations. In non-small-cell lung cancer, Eunice L. Kwak et al. (2010) showed ALK inhibition led to tumor shrinkage in most patients with ALK rearrangements (ClinicalTrials.gov NCT00585195), while Lecia V. Sequist et al. (2013) in "Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations" demonstrated afatinib's superiority over cisplatin-pemetrexed in EGFR-mutant cases. J-Y Douillard et al. (2000) reported irinotecan plus fluorouracil extended survival in metastatic colorectal cancer compared to fluorouracil alone.
Reading Guide
Where to Start
"Multidrug resistance in cancer: role of ATP–dependent transporters" by Michael M. Gottesman et al. (2002) is the starting point for beginners because it provides a foundational overview of a core resistance mechanism cited 5431 times across the field.
Key Papers Explained
Gottesman et al. (2002) "Multidrug resistance in cancer: role of ATP–dependent transporters" establishes efflux-mediated resistance, which Szakács et al. (2006) "Targeting multidrug resistance in cancer" builds on by proposing therapeutic strategies. Dasari and Tchounwou (2014) "Cisplatin in cancer therapy: Molecular mechanisms of action" and Siddik (2003) "Cisplatin: mode of cytotoxic action and molecular basis of resistance" detail DNA damage mechanisms and resistance. Kwak et al. (2010) "Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer" and Sequist et al. (2013) "Phase III Study of Afatinib or Cisplatin Plus Pemetrexed..." demonstrate targeted therapy successes and evolutions described in Kobayashi et al. (2005) and Sequist et al. (2011).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research extends resistance evolution studies from Sequist et al. (2011) "Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors" to combination therapies countering multidrug resistance as in Holohan et al. (2013) "Cancer drug resistance: an evolving paradigm". Focus shifts to genetic variants predicting topoisomerase inhibitor outcomes, building on irinotecan trials.
Papers at a Glance
Frequently Asked Questions
What role do ATP-dependent transporters play in cancer drug resistance?
ATP-dependent transporters, such as those discussed by Michael M. Gottesman et al. (2002) in "Multidrug resistance in cancer: role of ATP–dependent transporters", actively efflux chemotherapeutic agents from cancer cells, reducing intracellular drug levels and causing multidrug resistance. This mechanism impacts a broad range of anticancer drugs. Targeting these transporters remains a focus for overcoming resistance.
How does cisplatin exert its cytotoxic effects in cancer therapy?
Cisplatin induces cytotoxicity primarily through forming DNA adducts that trigger cell death pathways, as outlined by Shaloam Dasari and Paul Bernard Tchounwou (2014) in "Cisplatin in cancer therapy: Molecular mechanisms of action". Resistance arises from enhanced DNA repair and reduced uptake. Siddik (2003) in "Cisplatin: mode of cytotoxic action and molecular basis of resistance" further details these molecular bases.
What is the impact of ALK inhibition in non-small-cell lung cancer?
ALK inhibition in tumors with ALK rearrangements results in tumor shrinkage or stable disease in most patients, per Eunice L. Kwak et al. (2010) in "Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer" (NCT00585195). This targeted approach validates ALK as a therapeutic target. Resistance mechanisms evolve post-treatment.
How do EGFR mutations affect response to gefitinib in lung cancer?
EGFR mutations enable initial response to gefitinib in non-small-cell lung cancer, but secondary mutations like T790M drive relapse, as shown by Susumu Kobayashi et al. (2005) in "EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib". This highlights acquired resistance pathways. Genotypic evolution underlies histological changes during treatment.
What are the outcomes of irinotecan in colorectal cancer treatment?
Irinotecan combined with fluorouracil improves survival as first-line therapy for metastatic colorectal cancer compared to fluorouracil alone, according to J-Y Douillard et al. (2000) in "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial". This combination sets a standard for advanced disease. It targets topoisomerase I.
How does afatinib compare to cisplatin-pemetrexed in EGFR-mutant lung adenocarcinoma?
Afatinib, an irreversible ErbB blocker, outperforms cisplatin plus pemetrexed in progression-free survival for metastatic lung adenocarcinoma with EGFR mutations, as demonstrated by Lecia V. Sequist et al. (2013) in "Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations". It targets EGFR, HER2, and ErbB4 signaling. This supports irreversible inhibitors over chemotherapy.
Open Research Questions
- ? How can ATP-dependent transporters be selectively inhibited to reverse multidrug resistance without systemic toxicity?
- ? What secondary genetic alterations emerge in lung cancers developing resistance to ALK and EGFR inhibitors?
- ? Which genetic variants of topoisomerases best predict irinotecan toxicity and efficacy?
- ? Can dynamic monitoring of histological and genotypic changes predict and preempt resistance to targeted lung cancer therapies?
- ? What combinations of topoisomerase inhibitors with efflux pump blockers restore sensitivity in resistant colorectal cancers?
Recent Trends
The field maintains steady output at 53,210 works with sustained high citation rates for foundational papers like Gottesman et al. at 5431 citations, reflecting ongoing relevance of transporter-mediated resistance amid targeted therapy advances such as afatinib in Sequist et al. (2013).
2002No new preprints or news in the last 12 months indicate consolidation of mechanisms from 2000-2014 papers.
Emphasis persists on EGFR/ALK resistance dynamics from Kwak et al. and Kobayashi et al. (2005).
2010Research Cancer therapeutics and mechanisms with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer therapeutics and mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers